ROKIT HEALTHCARE Q1 2026 Revenue Surges 118% but Operating Loss Persists, Debt Ratio 936%

Consolidated revenue of KRW 8.06 billion (up 118% YoY from KRW 3.69 billion), operating loss of KRW 2.35 billion
Debt ratio of 936%, highly leveraged; raised KRW 62.5 billion via RCPS issuance, boosting cash to KRW 68.2 billion
Subsidiary ROKIT AMERICA filed Form S-1 for Nasdaq listing (expected price $9.50, maintaining ~90.48% stake)
Post-period: Signed 30 billion won JV MOU with UAE's MIG, and Saudi CKD AI license agreement with LifeHope
During Q1, 77,250 stock options exercised, new grants of 187,000 options
No dividend or share buyback plans